Autoantibodies against cardiac troponin I in patients with congestive heart failure
Düngen, Hans-Dirk, Platzeck, Maria, Vollert, Jörn, Searle, Julia, Müller, Christian, Reiche , Janett, Mehrhoff, Felix, Müller, Reinhold, and Möckel, Martin (2010) Autoantibodies against cardiac troponin I in patients with congestive heart failure. European Journal of Heart Failure, 12 (7). pp. 668-675.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1093/eurjhf/hfq088 ...
Aims: In this randomized, double-blind clinical study, we investigated the relationship between autoantibodies against cardiac troponin I (cTnI) and disease severity in elderly congestive heart failure (CHF) patients before and after titration of beta-blocker therapy. Methods and results: Anti-cTnI, cTnI, and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in blood from 138 patients (73 ± 5.6 years, 48% male) with CHF in American Heart Association stages A–C were measured at baseline and after titration of beta-blockers to maximal tolerated dose. Median follow-up period was 85 days. Anti-cTnI was measured using an experimental assay (Abbott Diagnostics) and is expressed as a relative value unit (RVU) in relation to the mean value of a low-level control sample. Anti-cTnI values in CHF patients were also compared with measurements taken in a normal reference population of 300 healthy individuals (50% male). Cardiac troponin I and NT-proBNP levels were measured using routine assays (Architect® Abbott Diagnostics and Roche Diagnostics®). Median anti-cTnI was 0.53 and 0.56 RVU in healthy and CHF subjects, respectively (P = n.s.), and increased significantly to 0.67 RVU (P < 0.001) after beta-blocker titration. Mean cTnI values were 0.021 µg/L at baseline and fell significantly to 0.0046 µg/L at follow-up (P < 0.001). Median NT-proBNP values were 352 ng/L at baseline and 414 ng/L after titration (P = n.s.). In contrast to NT-proBNP and cTnI, anti-cTnI was not associated with the severity of CHF at baseline or follow-up. Conclusion: Levels of anti-cTnI tend to increase in elderly patients with CHF following titration of beta-blocker therapy but do not correlate with disease severity. Anti-cTnI is not a useful biomarker for heart failure diagnosis, prognosis, or monitoring. In contrast, levels of cTnI decreased following therapy and did correlate with disease severity.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||heart failure, biomarkers, troponin, autoantibodies, NT-proBNP|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111706 Epidemiology @ 50%|
11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111799 Public Health and Health Services not elsewhere classified @ 50%
|SEO Codes:||92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920499 Public Health (excl. Specific Population Health) not elsewhere classified @ 100%|
|Deposited On:||07 May 2011 08:27|
|Last Modified:||17 May 2013 01:28|
Last 12 Months: 0
|Citation Counts with External Providers:||Web of Science: 8|
Repository Staff Only: item control page